NASDAQ · STOCK
Vertex Pharmaceuticals
$498.39
52W $362.50 – $533.67
60/100
$115.02B
30.0
0.29
⚠
Lean Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily trend: uptrend.
- Daily uptrend conflicts with weekly downtrend — buying against the higher timeframe trend is higher risk.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 10.4% downside vs 1.5% upside.
AI Investment Committee
Committee Consensus
As of July 08, 2026
Overall Committee Score
60/100
The AI Investment Committee is an ensemble of six specialized analytical agents: Value Analyst, Technical Analyst, Growth Analyst, Risk Analyst, Macro Analyst, and News Analyst. Each agent independently evaluates VRTX using dedicated data signals, then the committee aggregates their verdicts into a final score and recommendation. This multi-agent approach reduces individual model bias and provides a more balanced investment assessment.
Technical Analysis
RSI (14)
65.2
Neutral
MACD Histogram
4.529
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Mixed
Support
$458.47
Resistance
$519.39
Bollinger %B
0.78
Inside Bands
Price vs Moving Averages
EMA 9
$505.66
Below
EMA 21
$484.49
Above
EMA 50
$464.60
Above
EMA 200
$451.37
Above
Fundamental Analysis
Valuation
34
Growth
60
Profitability
100
Financial Health
100
Valuation
P/E Ratio
30.0×
P/B Ratio
6.16×
PEG Ratio
—
Dividend Yield
—
52W High
$533.67
52W Low
$362.50
Quality & Growth
ROE
2393.0%
ROA
1718.0%
Gross Margin
8624.0%
Operating Margin
3831.0%
Revenue Growth YoY
+1008.0%
Debt / Equity
0.01
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 30.0 (rich relative to a 15-40x range); Price-to-book of 6.2x; Revenue growth (YoY) of 10.1%; Return on equity of 23.9%; Return on assets of 17.2%; Net margin of 35.5%; Gross margin of 86.2%; Current ratio of 2.90 (healthy short-term liquidity); Debt-to-equity of 0.01; Earnings-history trend unavailable; growth based on TTM year-over-year only.
Key Risks
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 10.4% downside vs 1.5% upside.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full VRTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile